SearcharxivSearch

arXiv subjects

Peter K. Kimani

Publications and source records attributed to Peter K. Kimani.

3 recordsLinked to original sources

Unbiased estimation in two-stage adaptive enrichment designs

Recent advances in biomedical research have identified an increasing number of biomarkers associated with heterogeneity in patient responses to medical treatments. When a treatment is suspected to benefit certain patient subpopulations, adaptive enrichment designs may be more efficient and ethical. In such designs, an interim analysis is incorporated during the trial to select patient subpopulations for which the experimental treatment appears promising, according to predefined subpopulation selection rules. However, data-dependent selection can induce selection bias, causing conventional maximum likelihood estimators (MLEs) to overestimate the treatment effect in the selected patient subgroup. Existing inference methods for addressing this bias are typically rule-specific, highlighting the need for an estimation framework that accommodate a broader class of subpopulation selection rules. In this work, we define a general class of subpopulation selection rules based on the sample space partition condition and provide a systematic derivation that yields a unified formula for the Uniformly Minimum Variance Conditional Unbiased Estimator (UMVCUE). This generality allows our formulation to encompass a wide spectrum of adaptive enrichment designs, eliminating the necessity for case-specific derivations for each new design. Extensive simulations confirm the unbiasedness of the proposed UMVCUE, ensuring that therapeutic benefits are not overestimated. By bridging the gap between flexible interim subpopulation selection and rigorous statistical inference, our framework has the potential to facilitate the implementation of diverse subpopulation selection rules with greater ease in real-world trials and promote more efficient and ethical drug development.

stat.ME

Confidence intervals for two-stage adaptive designs with subpopulation selection

We consider clinical trials in which an experimental treatment is compared with a control in pre-specified patient subpopulations. In such settings, adaptive enrichment designs allow the enrolled population to be modified at an interim analysis, with subpopulations selected according to preplanned rules. Since these interim decisions are data-dependent, valid statistical inference must account for them. We focus on constructing confidence intervals for the treatment effect in the selected population. Confidence interval methods that ignore the possibility of population modification may fail to achieve the desired coverage probability. We propose a new approach that constructs confidence intervals with exact nominal coverage conditional on the interim decision. Importantly, our method applies to a broad class of adaptive enrichment designs, rather than a single specific design. Our method involves deriving the distribution of the naive estimator of the treatment effect in the selected population conditional on the interim decision and inverting uniformly most accurate unbiased tests to obtain the confidence interval. We provide an efficient computational procedure and show through extensive simulations that the resulting confidence intervals satisfy the theoretical coverage guarantees.

stat.ME

Efficient adaptive designs for clinical trials of interventions for COVID-19

The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this paper we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.

q-bio.QM